Table 1.
Baseline characteristics of the research population
| References | Country | Design | Follow-up (weeks) | Age | n | Group | Types of fillers (trade name) | Mean vol. injection, ml (mean±SD) | Injection materials | Outcomes |
|---|---|---|---|---|---|---|---|---|---|---|
| Yang et al.5 2019a | Korea | RCT | 48 | 20–65 | 36 | Intervention | Hyaluronic acid (Chaeum Shape) | 19.14±1.4 | 20 mg/ml HA cross-linked | Penile girth, satisfaction rate appearance, sexual satisfaction level, side effects |
| 34 | Control | Polylactic acid (PowerFill) | 20.59±1.28 | 10 g/3 ml microparticles PLA | ||||||
| Yang et al.22 2019b | Korea | RCT | 24 | 19–65 | 37 | Intervention | Hyaluronic acid (Neuramis Deep) | 20.8±1.5 | 20 mg/ml HA cross-linked | Penile girth, satisfaction rate appearance, sexual satisfaction level, side effects |
| 35 | Control | Polylactic acid (PowerFill) | 21.8±1.7 | 10 g/3 ml microparticles PLA | ||||||
| Yang et al.6 2020 | Korea | RCT | 72 | 20–66 | 33 | Intervention | Hyaluronic acid (Hyafilia Impact) | 16.4±2.7 | 20 mg HA cross-linked+3 mg lidocaine/ml | Penile girth, satisfaction rate appearance, sexual satisfaction level, side effects |
| 34 | Control | Polylactic acid (PowerFill) | 17.7±2.3 | 10 g/3 ml microparticles PLA | ||||||
| Ahn et al.17 | Korea | RCT | 24 | 20–65 | 32 | Intervention | Hyaluronic acid (Doublofill) | 15–22 | 23 mg HA cross-linked+3 mg lidocaine/2 ml | Penile girth, sexual satisfaction rate, side effects |
| 32 | Control | Polylactic acid (PowerFill) | 15–22 | 10 g/3 ml microparticles PLA |
PLA, polylactic acid.